Mydecine Innovations Group Partners with Microdose to Present a Webinar on Psychedelic Drug Development

← Back to all news
February 16, 2021

Published at

Mydecine Speaker Series III

Toronto, Ontario Feb 16, 2021 ( –

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced today that the Company has partnered with Microdose Psychedelic Insights (“Microdose”), a leader in B2B psychedelic intelligence, to present a free, three-part live video discussion series titled “Mydecine Speaker Series” covering Research, Psychedelic Therapies, PTSD, Microdosing, and Drug Discovery.

The Mydecine Speaker Series is dedicated to exploring the incredible findings around current psychedelic research and what the path to mainstream acceptance looks like. Moderated by Debra Borchardt, Green Market Report, Co-Founder and CEO., the panelists will discuss if Psychedelic Drug Design can Improve Safety and Efficacy for Medicine.

The third Mydecine Speaker Series event will feature Mydecine Scientific Advisory Board Member Dr. Denton Hoyer, Mydecine Innovations Group, Drug Discovery Consultant, the Chief Scientific Officer Robert Roscow, and Paul A. Frewen, Ph.D., C.Psych., University of Western Ontario, Associate Professor.

Details and schedule of the third event are as follows:

Mydecine Speaker Series III – Drug Development: Can Psychedelic Drug Design Improve Safety and Efficacy for Medicine? starts on Thursday, Feb 18th, 2021 1:30 pm – 3:00 pm EST hosted by Mydecine Innovations Group Inc. moderated by Debra Borchardt, Green Market Report, Co-Founder and CEO.


Debra Borchardt, Green Market Report, Co-Founder and CEO

Debra Borchardt is the Co-founder and CEO of the financial news website Green Market Report. She is an award-winning journalist with a Masters’s Degree in Business Journalism from New York University. Debra worked alongside Jim Cramer for eight years before embarking on a solo career. Prior to becoming a financial journalist, Debra worked on Wall Street and was a Vice President at Bear Stearns, where she worked for 15 years.


Robert Roscow, MA, Mydecine Innovations Group, Chief Scientific Officer & Co-Founder

Robert Roscow, MA (Chief Scientific Officer & Co-Founder). Mr. Roscow is a highly educated geneticist with an impressive knowledge of multiple arts of science. He has spent his academic and professional careers looking for valuable and unique active medicinal compounds found in nature. The last two companies Mr. Roscow applied his innovations to were Canopy Growth and ebbu where he was the head of their genetics divisions.

Mr. Roscow has already leveraged expertise in genomics, evolution, and molecular biology to maximize the industrial production of cannabinoids and their use in a pharmacological context. His work has resulted in multiple patent filings and accolades in publications ranging from Nature to Rolling Stone. Now, Mr. Roscow has set his focus on the vast healing potential of the safe and effective compounds found in fungi.

Paul A. Frewen, Ph.D., C.Psych., University of Western Ontario, Associate Professor

Paul Frewen joined the departments of psychiatry and psychology at the University of Western Ontario in London, Ontario, Canada in September 2008. He completed his doctorate in clinical psychology at Western and his post-doctoral residency at the Royal Ottawa Mental Health Centre. He has chaired the Traumatic Stress Section of the Canadian Psychological Association (CPA) and is the current chair of the practice committee of the American Psychological Association (APA) Psychological Trauma Division. He received the President’s Early Research Award from the CPA in 2010, Early Career Awards from the Traumatic Stress sections of the American and Canadian Psychological Associations in 2013 and 2014, and the Scientist-Practitioner Early Career Award from the CPA in 2014. He has authored over 100 peer-reviewed articles on the subjects of trauma, affect regulation, mindfulness, dissociation, and the self, primarily utilizing functional neuroimaging and psychometrics approaches.

Dr. Denton Hoyer, Mydecine Innovations Group, Drug Discovery Consultant

Dr. Hoyer has been involved in drug discovery at leading pharmaceutical companies and research institutions for the last 30 years. He holds numerous patents and has been published extensively in the field of medicinal chemistry and drug research. Dr. Hoyer has unparalleled expertise in computational chemistry enabled probe molecule design, drug design, and optimization, synthetic planning and execution, evaluation of chemical novelty, and intellectual property assessment and strategies. Dr. Hoyer is currently on the scientific advisory board at Mydecine Innovations Group.


February 18th, 2021 at 13:30 p.m. – 3:00 p.m. Eastern  

Registration site:


In each webinar, 3 to 4 featured thought leaders in the psychedelic space will give their expert perspective on the current and future research, findings, and their applications to the marketplace. The participants will engage in deep and intimate conversations followed by a Q&A period with the audience.

About Microdose Psychedelic Insights

Microdose Psychedelic Insights aims to unlock the potential of psychedelics through Industry events, market intelligence, original, evidence-based content, strategy, and community. We enable and empower society at large to make better, more mindful decisions about psychedelics and their intersection with healthcare, medicine and personal growth. We work with the industry’s most influential stakeholders, some of the world’s best-known brands and an unrivaled network of scientists, researchers, analysts, innovators, investors, and advisors.

About Mydecine Innovations Group

Mydecine Innovations Group (CSE: MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval throgh Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.

At the heart of Mydecine’s core philosophy is that psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best-accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply. Mydecine has also successfully completed multiple acquisitions since its inception.

Learn more at:

Debra Borchardt
Robert Roscow
Denton Hoyer
Paul A Frewen